We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 18, 2020

Venetoclax Plus Rituximab in Relapsed CLL

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
J. Clin. Oncol 2020 Sep 28;[EPub Ahead of Print], AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D'Rozario, S Assouline, C Owen, T Robak, J de la Serna, U Jaeger, G Cartron, M Montillo, J Dubois, E Eldering, C Mellink, AM Van Der Kevie-Kersemaekers, SY Kim, B Chyla, E Punnoose, CR Bolen, ZJ Assaf, Y Jiang, J Wang, M Lefebure, M Boyer, K Humphrey, JF Seymour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading